West Pharmaceutical Services delivered a robust performance in the third quarter of 2026, significantly exceeding analyst expectations for both top and bottom-line results. Growth was primarily fueled by double-digit organic expansion in its Proprietary Products segment, particularly within the biologics market group. Consequently, management raised its full-year 2026 net sales and adjusted EPS guidance, reflecting confidence in sustained momentum for its high-value product lines.
Key Highlights
- Proprietary Products segment revenue grew 16.6% organically to $728.8 million, driven by a 20.3% organic increase in High-Value Product (HVP) Components.
- Net sales of $874.5 million exceeded the estimate of $827.12 million, representing 11.9% total organic growth despite a divestiture impact.
- Adjusted-diluted EPS of $2.66 surged 35.7% year-over-year, comfortably beating the $2.18 analyst estimate through favorable product mix and operational leverage.
- The company increased its full-year 2026 adjusted-diluted EPS guidance range to $9.38 - $9.48, a significant lift from the previous $8.85 - $9.05 range.
- Performance in the West Vantage segment remained a headwind, with reported sales declining 7.3% to $145.7 million due to the conclusion of specific customer contracts.